Literature DB >> 26430328

Dystrophic calcification in muscles of legs in calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia syndrome: Accurate evaluation of the extent with (99m)Tc-methylene diphosphonate single photon emission computed tomography/computed tomography.

Partha Sarathi Chakraborty1, Sellam Karunanithi1, Varun Singh Dhull1, Kunal Kumar1, Madhavi Tripathi1.   

Abstract

We present the case of a 35-year-old man with calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly and telangiectasia variant scleroderma who presented with dysphagia, Raynaud's phenomenon and calf pain. (99m)Tc-methylene diphosphonate bone scintigraphy was performed to identify the extent of the calcification. It revealed extensive dystrophic calcification in the left thigh and bilateral legs which was involving the muscles and was well-delineated on single photon emission computed tomography/computed tomography. Calcinosis in scleroderma usually involves the skin but can be found in deeper periarticular tissues. Myopathy is associated with a poor prognosis.

Entities:  

Keywords:  99mTc-methylene diphosphonate bone scan; Raynaud's phenomenon; and telangiectasia; calcinosis; dystrophic calcification; esophageal dysmotility; sclerodactyly; single photon emission computed tomography/computed tomography

Year:  2015        PMID: 26430328      PMCID: PMC4579629          DOI: 10.4103/0972-3919.159695

Source DB:  PubMed          Journal:  Indian J Nucl Med        ISSN: 0974-0244


A 35-year-old man with calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia (CREST) syndrome presented with dysphagia since 1-year; Raynaud's phenomenon since 2 years; swelling and pain in bilateral calf muscles since 3 years. On examination, bilateral calf muscles were swollen and hard in consistency. Also noted were diffuse telangiectasias and sclerodactyly. Anti-nuclear antibody level was 1:320 speckled pattern and creatine phosphokinase levels were elevated (400 IU/l; normal: 60–174 IU/l). Anti-centromere antibody levels were mildly elevated (20.01) where a value of ≤20 is considered negative. Serum calcium and phosphate levels were normal (9.7 and 3.4 mg/dl, respectively). A radiograph of bilateral legs revealed multiple discrete radiodensities arranged linearly along the bony axis of the leg; predominantly in the inferior half along the muscle fibers. The patient was referred for 99mTc-methylene diphosphonate (MDP) bone scintigraphy (BS) to rule out other sites of involvement. BS revealed areas of increased uptake in left thigh and bilateral leg region [Figure 1a, anterior; Figure 1b, posterior view; arrows]. Single photon emission computed tomography/computed tomography (SPECT/CT) of the leg region was performed in the same setting and it revealed calcification in the subcutaneous region and muscles of legs with 99mTc-MDP uptake [Figure c–f, arrows]. Dystrophic calcification is deposition of calcium salts in degenerated tissues in the presence of normal calcium and phosphorus levels in the body.[1] The most common site is heart muscle and valves.[2] A number of causes can give rise to calcification in the muscles of legs like dermatomyositis, polymyositis, diabetic myonecrosis, etc.[3] CREST syndrome, a limited form of scleroderma, is a multisystem connective tissue disorder.[4] Scleroderma myopathy is a heterogenous entity comprising of patients either with primary inflammatory or fibrotic features.[5] There is a female preponderance, and anti-centromere antibody may be negative. Furthermore, patients with internal organ involvement are more prone to develop myopathy.[6] Early recognition of muscle involvement may result in the initiation of time appropriate therapy and thereby improving prognosis. The findings on BS are sometimes difficult to interpret because of various forms of extraskeletal uptake. Addition of SPECT/CT as seen in the present case often helps in the exact localization of extra-osseous uptake.[7] Extra-osseous uptake of MDP can be seen in a number of conditions like metastatic pleural or pericardial effusion, hepatic metastases, metastases of osteosarcoma; primary tumors like neuroblastoma; metabolic causes of serum hypercalcemia like renal failure, sarcoidosis, amyloidosis, myositis ossificans, ischemia, cellulitis, necrosis etc.[8] Muscle involvement is a poor prognostic factor in systemic sclerosis.[9] Calcification in muscles in scleroderma demonstrated on CT has been reported.[10] In this case, BS along with SPECT/CT helped in correct localization of the sites of calcification.
Figure 1

99mTc-methylene diphosphonate (99mTc-MDP) bone scintigraphy revealed areas of increased uptake in left thigh and bilateral leg region (a, anterior; b, posterior view; arrows). Single photon emission computed tomography/computed tomography of the leg region revealed calcification in the subcutaneous region and muscles of legs with 99mTc-MDP uptake (c-f, arrows)

99mTc-methylene diphosphonate (99mTc-MDP) bone scintigraphy revealed areas of increased uptake in left thigh and bilateral leg region (a, anterior; b, posterior view; arrows). Single photon emission computed tomography/computed tomography of the leg region revealed calcification in the subcutaneous region and muscles of legs with 99mTc-MDP uptake (c-f, arrows)
  10 in total

Review 1.  Nonosseous abnormalities on bone scans.

Authors:  Issa Loutfi; B David Collier; Ahmed M Mohammed
Journal:  J Nucl Med Technol       Date:  2003-09

2.  A unique case of dystrophic calcification in masseter: a diagnostic challenge.

Authors:  Chetana S Naik; Archana A Arya; S D Deshmukh; Vandana Gaopande
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2011-12-02

3.  Cryoglobulinemic vasculitis in a patient with CREST syndrome.

Authors:  Rebecca L Hurst; Florentina Berianu; William W Ginsburg; Christopher J Klein; Janean K Englestad; Kathleen D Kennelly
Journal:  J Clin Neurosci       Date:  2014-05-19       Impact factor: 1.961

Review 4.  Myopathy in scleroderma, its identification, prevalence, and treatment: lessons learned from cohort studies.

Authors:  Julie J Paik; Andrew L Mammen; Fredrick M Wigley; Allan C Gelber
Journal:  Curr Opin Rheumatol       Date:  2014-03       Impact factor: 5.006

5.  Myocardial fibre calcification.

Authors:  J McClure; A S Pieterse; D J Pounder; P S Smith
Journal:  J Clin Pathol       Date:  1981-10       Impact factor: 3.411

Review 6.  SPECT-CT for characterization of extraosseous uptake of 99mTc-methylene diphosphonate on bone scintigraphy.

Authors:  Ramya Soundararajan; Niraj Naswa; Punit Sharma; Sellam Karunanithi; Aftab Hasan Nazar; Kalpa Jyoti Das; Chandrasekhar Bal; Arun Malhotra; Rakesh Kumar
Journal:  Diagn Interv Radiol       Date:  2013 Sep-Oct       Impact factor: 2.630

7.  Clinical and laboratory features of scleroderma patients developing skeletal myopathy.

Authors:  Yoshihiro Mimura; Hironobu Ihn; Masatoshi Jinnin; Yoshihide Asano; Kenichi Yamane; Kunihiko Tamaki
Journal:  Clin Rheumatol       Date:  2004-08-20       Impact factor: 2.980

8.  Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort.

Authors:  M Jung; A Bonner; M Hudson; M Baron; J E Pope
Journal:  Scand J Rheumatol       Date:  2014-03-21       Impact factor: 3.641

9.  A case of linear scleroderma with muscle calcification.

Authors:  M Jinnin; H Ihn; Y Asano; K Yamane; N Yazawa; K Tamaki
Journal:  Br J Dermatol       Date:  2002-06       Impact factor: 9.302

10.  Calcific myonecrosis and the role of imaging in the diagnosis: a case report.

Authors:  Atsushi Okada; Masahito Hatori; Masami Hosaka; Munenori Watanuki; Eiji Itoi
Journal:  Ups J Med Sci       Date:  2009       Impact factor: 2.384

  10 in total
  1 in total

1.  Calcified peritoneal metastasis identified on 18F-fluoride positron emission tomography/computed tomography: Importance of extraosseous uptake of F-18 fluoride.

Authors:  Priyanka Verma; Piyush Chandra; Archi Agrawal; Nilendu Purandare; Sneha Shah; Venkatesh Rangarajan
Journal:  Indian J Nucl Med       Date:  2016 Apr-Jun
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.